(Q48682192)

English

Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial

scientific article published on 8 June 2016

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

14 February 2018

http://europepmc.org/abstract/MED/27291994

Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

14 February 2018

http://europepmc.org/abstract/MED/27291994

phase II clinical trial

0 references

multiple sclerosis

0 references

multicenter clinical trial

1 reference

based on heuristic

inferred from title

object named as

Lisa Walker

24

0 references

object named as

David Allan

3

0 references

object named as

Brian Hutton

15

0 references

object named as

Timothy Ramsay

22

0 references

Dean A Fergusson

object named as

Dean Fergusson

11

0 references

6

object named as

Amit Bar-Or

1 reference

Europe PubMed Central

PubMed publication ID

14 February 2018

http://europepmc.org/abstract/MED/27291994

author name string

Harold L Atkins

1

1 reference

Europe PubMed Central

PubMed publication ID

14 February 2018

http://europepmc.org/abstract/MED/27291994

Marjorie Bowman

2

1 reference

Europe PubMed Central

PubMed publication ID

14 February 2018

http://europepmc.org/abstract/MED/27291994

Grizel Anstee

4

1 reference

Europe PubMed Central

PubMed publication ID

14 February 2018

http://europepmc.org/abstract/MED/27291994

Douglas L Arnold

5

1 reference

Europe PubMed Central

PubMed publication ID

14 February 2018

http://europepmc.org/abstract/MED/27291994

Isabelle Bence-Bruckler

7

1 reference

Europe PubMed Central

PubMed publication ID

14 February 2018

http://europepmc.org/abstract/MED/27291994

Paul Birch

8

1 reference

Europe PubMed Central

PubMed publication ID

14 February 2018

http://europepmc.org/abstract/MED/27291994

Christopher Bredeson

9

1 reference

Europe PubMed Central

PubMed publication ID

14 February 2018

http://europepmc.org/abstract/MED/27291994

Jacqueline Chen

10

1 reference

Europe PubMed Central

PubMed publication ID

14 February 2018

http://europepmc.org/abstract/MED/27291994

Mike Halpenny

12

1 reference

Europe PubMed Central

PubMed publication ID

14 February 2018

http://europepmc.org/abstract/MED/27291994

Linda Hamelin

13

1 reference

Europe PubMed Central

PubMed publication ID

14 February 2018

http://europepmc.org/abstract/MED/27291994

Lothar Huebsch

14

1 reference

Europe PubMed Central

PubMed publication ID

14 February 2018

http://europepmc.org/abstract/MED/27291994

Pierre Laneuville

16

1 reference

Europe PubMed Central

PubMed publication ID

14 February 2018

http://europepmc.org/abstract/MED/27291994

Yves Lapierre

17

1 reference

Europe PubMed Central

PubMed publication ID

14 February 2018

http://europepmc.org/abstract/MED/27291994

Hyunwoo Lee

18

1 reference

Europe PubMed Central

PubMed publication ID

14 February 2018

http://europepmc.org/abstract/MED/27291994

Lisa Martin

19

1 reference

Europe PubMed Central

PubMed publication ID

14 February 2018

http://europepmc.org/abstract/MED/27291994

Sheryl McDiarmid

20

1 reference

Europe PubMed Central

PubMed publication ID

14 February 2018

http://europepmc.org/abstract/MED/27291994

Paul O'Connor

21

1 reference

Europe PubMed Central

PubMed publication ID

14 February 2018

http://europepmc.org/abstract/MED/27291994

Mitchell Sabloff

23

1 reference

Europe PubMed Central

PubMed publication ID

14 February 2018

http://europepmc.org/abstract/MED/27291994

Mark S Freedman

25

1 reference

Europe PubMed Central

PubMed publication ID

14 February 2018

http://europepmc.org/abstract/MED/27291994

language of work or name

0 references

publication date

8 June 2016

1 reference

Europe PubMed Central

PubMed publication ID

14 February 2018

http://europepmc.org/abstract/MED/27291994

1 reference

Europe PubMed Central

PubMed publication ID

14 February 2018

http://europepmc.org/abstract/MED/27291994

388

1 reference

Europe PubMed Central

PubMed publication ID

14 February 2018

http://europepmc.org/abstract/MED/27291994

10044

1 reference

Europe PubMed Central

PubMed publication ID

14 February 2018

http://europepmc.org/abstract/MED/27291994

576-585

1 reference

Europe PubMed Central

PubMed publication ID

14 February 2018

http://europepmc.org/abstract/MED/27291994

Mechanisms of neurodegeneration and axonal dysfunction in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930169-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930169-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Hematopoietic SCT for the treatment of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930169-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930169-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Autologous hematopoietic cell transplantation following high-dose immunosuppressive therapy for advanced multiple sclerosis: long-term results

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930169-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Autologous haematopoietic stem cell transplantation with an intermediate intensity conditioning regimen in multiple sclerosis: the Italian multi-centre experience

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930169-6

7 January 2021

based on heuristic

inferred from DOI database lookup

The natural history of multiple sclerosis: a geographically based study. 3. Multivariate analysis of predictive factors and models of outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930169-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930169-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Criteria for an increased specificity of MRI interpretation in elderly subjects with suspected multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930169-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Immune ablation followed by autologous hematopoietic stem cell transplantation for the treatment of poor prognosis multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930169-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Regimen-related toxicity in patients undergoing bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930169-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Local magnetization transfer ratio signal inhomogeneity is related to subsequent change in MTR in lesions and normal-appearing white-matter of multiple sclerosis patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930169-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Accurate, robust, and automated longitudinal and cross-sectional brain change analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930169-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Diminished Th17 (not Th1) responses underlie multiple sclerosis disease abrogation after hematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930169-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930169-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930169-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Mitoxantrone prior to interferon beta-1b in aggressive relapsing multiple sclerosis: a 3-year randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930169-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: treatment response factors in a 5 year follow-up observational study of 100 consecutive patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930169-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Transfer of vitiligo after allogeneic bone marrow transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930169-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Cytotoxic chemotherapy preceding apheresis of peripheral blood progenitor cells can affect the early reconstitution phase of naive T cells after autologous transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930169-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparative outcomes of donor graft CD34+ selection and immune suppressive therapy as graft-versus-host disease prophylaxis for patients with acute myeloid leukemia in complete remission undergoing HLA-matched sibling allogeneic hematopoietic cell t

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930169-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Association of nonmyeloablative hematopoietic stem cell transplantation with neurological disability in patients with relapsing-remitting multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930169-6

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for relapsing-remitting multiple sclerosis (HALT-MS): a 3-year interim report

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930169-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Autologous hematopoietic stem cell transplantation in multiple sclerosis: a phase II trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930169-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Characterising aggressive multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930169-6

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose immunoablation with autologous haematopoietic stem cell transplantation in aggressive multiple sclerosis: a single centre 10-year experience.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930169-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term results of stem cell transplantation for MS: A single-center experience

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930169-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Autologous hematopoietic stem cell transplantation with reduced-intensity conditioning in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930169-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: the Swedish experience.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930169-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Hematopoietic stem cell transplantation for progressive multiple sclerosis: failure of a total body irradiation-based conditioning regimen to prevent disease progression in patients with high disability scores

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930169-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Autologous hematopoietic stem cell transplantation following pulsed cyclophosphamide in a severely disabled patient with malignant multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930169-6

7 January 2021

based on heuristic

inferred from DOI database lookup

A Three-Year Study of Brain Atrophy after Autologous Hematopoietic Stem Cell Transplantation in Rapidly Evolving Secondary Progressive Multiple Sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930169-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Autologous hematopoietic stem cell transplantation for autoimmune diseases: an observational study on 12 years' experience from the European Group for Blood and Marrow Transplantation Working Party on Autoimmune Diseases.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930169-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Transplantation for autoimmune diseases in north and South America: a report of the Center for International Blood and Marrow Transplant Research

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2930169-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(16)30169-6

1 reference

Europe PubMed Central

PubMed publication ID

14 February 2018

http://europepmc.org/abstract/MED/27291994

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

14 February 2018

http://europepmc.org/abstract/MED/27291994

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q48682192&oldid=2206573268"